Celltrion, Inc.

Industry

  • Pharmaceuticals
    • OTC, Consumer
    • Generic Drugs
  • Digital Health
    • Disease Management
  • Biotechnology
    • Large Molecule
      • Antibodies

Other Names/Subsidiaries

  • Bio CDMO
  • Celltrion Asia Pacific PTE
  • Celltrion Biopharma
  • Celltrion Europe
  • Celltrion Global Safety Data Centre
  • Celltrion Group Hong Kong
  • Celltrion Healthcare Hungary Kft
  • Celltrion Pharm
  • Celltrion Pharma USA
  • Shanghai Vcell Biotech
  • Vcell Healthcare
See more in Biomedtracker

Latest on Celltrion, Inc.

Pink Sheet

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

On top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo

Scrip

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

On top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo

Generics Bulletin

Celltrion Plans Multiple US Biosimilar Launches In An ‘Exciting And Momentous’ Year

 
• By Dave Wallace

If Celltrion’s US biosimilars business was already picking up speed, then that momentum is only going to continue in 2025, according to Celltrion USA’s chief commercial officer Thomas Nusbickel. In an

Scrip

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By Jung Won Shin

Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the